SEC Comment Letter 0000000000-22-013668 to Apollomics Inc. (APLM, APLMW) (CIK 0001944885) (APLM)
Apollomics Inc. (APLM, APLMW) (CIK 0001944885)
Date: Dec. 19, 2022 · CIK: 0001944885 · Accession: 0000000000-22-013668
AI Filing Summary & Sentiment
File numbers found in text: 333-268525
Letter
United States securities and exchange commission logo December 19, 2022 Guo-Liang Yu Chief Executive Officer Apollomics Inc. 989 E. Hillsdale Blvd., Suite 220 Foster City, CA 94404 Re:Apollomics Inc. Amendment No. 1 to Registration Statement on Form F-4 Filed December 15, 2022 File No. 333-268525 Dear Guo-Liang Yu: We have reviewed your amended registration statement and have the following comments. In some of our comments, we may ask you to provide us with information so we may better understand your disclosure. Please respond to this letter by amending your registration statement and providing the requested information. If you do not believe our comments apply to your facts and circumstances or do not believe an amendment is appropriate, please tell us why in your response. After reviewing any amendment to your registration statement and the information you provide in response to these comments, we may have additional comments. Unless we note otherwise, our references to prior comments are to comments in our December 5, 2022 letter. Amendment No. 1 to Registration Statement on Form F-4 Information about Apollomics Drug Candidate Development Status, page 215 1.We note your revised disclosure in response to prior comment 6 and reissue in part. Please remove the third party trials from your pipeline table as disclosure indicates you do not have any direct financial interest in the development of these product candidates by third parties. We will not object to a narrative discussion of your rights to access clinical trial data and potential to benefit from feedback from regulators.
FirstName LastNameGuo-Liang Yu Comapany NameApollomics Inc. December 19, 2022 Page 2 FirstName LastName Guo-Liang Yu Apollomics Inc. December 19, 2022 Page 2 Employment Agreements, page 337 2.Please file the employment agreements entered into with your executive officers as exhibits to your registration statement. Refer to Item 601(b)(10)(ii)(A) of Regulation S-K for guidance. You may contact Christine Torney at 202-551-3652 or Kevin Vaughn at 202-551-3494 if you have questions regarding comments on the financial statements and related matters. Please contact Tyler Howes at 202-551-3370 or Christine Westbrook at 202-551-5019 with any other questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Daniel Nussen, Esq.
Show Raw Text
United States securities and exchange commission logo
December 19, 2022
Guo-Liang Yu
Chief Executive Officer
Apollomics Inc.
989 E. Hillsdale Blvd., Suite 220
Foster City, CA 94404
Re:Apollomics Inc.
Amendment No. 1 to Registration Statement on Form F-4
Filed December 15, 2022
File No. 333-268525
Dear Guo-Liang Yu:
We have reviewed your amended registration statement and have the following
comments. In some of our comments, we may ask you to provide us with information so we
may better understand your disclosure.
Please respond to this letter by amending your registration statement and providing the
requested information. If you do not believe our comments apply to your facts and
circumstances or do not believe an amendment is appropriate, please tell us why in your
response.
After reviewing any amendment to your registration statement and the information you
provide in response to these comments, we may have additional comments. Unless we note
otherwise, our references to prior comments are to comments in our December 5, 2022 letter.
Amendment No. 1 to Registration Statement on Form F-4
Information about Apollomics
Drug Candidate Development Status, page 215
1.We note your revised disclosure in response to prior comment 6 and reissue in
part. Please remove the third party trials from your pipeline table as disclosure indicates
you do not have any direct financial interest in the development of these product
candidates by third parties. We will not object to a narrative discussion of your rights to
access clinical trial data and potential to benefit from feedback from regulators.
FirstName LastNameGuo-Liang Yu
Comapany NameApollomics Inc.
December 19, 2022 Page 2
FirstName LastName
Guo-Liang Yu
Apollomics Inc.
December 19, 2022
Page 2
Employment Agreements, page 337
2.Please file the employment agreements entered into with your executive officers as
exhibits to your registration statement. Refer to Item 601(b)(10)(ii)(A) of Regulation S-K
for guidance.
You may contact Christine Torney at 202-551-3652 or Kevin Vaughn at 202-551-3494 if
you have questions regarding comments on the financial statements and related matters. Please
contact Tyler Howes at 202-551-3370 or Christine Westbrook at 202-551-5019 with any other
questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Daniel Nussen, Esq.